Halozyme rockets 30% on potential $515M deal with Pfizer
This article was originally published in Scrip
Shares of Halozyme Therapeutics soared 30% on 21 December after it revealed it had inked a worldwide deal with Pfizer to develop and commercialize subcutaneous biologics using recombinant human hyaluronidase.
You may also be interested in...
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.